Trials / Active Not Recruiting
Active Not RecruitingNCT05970224
A Study to Evaluate the Safety, Tolerability and the Effects of Ixodes Ricinus-Contact Phase Inhibitor (Ir-CPI) in Adult Patients With Spontaneous Intracerebral Haemorrhage
A Phase IIa, Randomized, Open-label, Proof-of-Concept Study to Evaluate Safety, Tolerability and Efficacy of Ir-CPI in Patients With Spontaneous Intracerebral Haemorrhage
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 23 (actual)
- Sponsor
- Bioxodes S.A. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to provide a first assessment of safety, tolerability and efficacy of Ir-CPI, administered on top of standard-of-care, on secondary brain injury in patients with spontaneous intracerebral haemorrhage.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ir-CPI | Participants receive a single intravenous dose of Ir-CPI during 48 hours |
Timeline
- Start date
- 2023-11-17
- Primary completion
- 2026-03-20
- Completion
- 2027-07-01
- First posted
- 2023-08-01
- Last updated
- 2026-03-27
Locations
10 sites across 1 country: Belgium
Source: ClinicalTrials.gov record NCT05970224. Inclusion in this directory is not an endorsement.